Pfizer Cuts Late-Stage Asset For Rare Cardiovascular Acquired Via $11.4B Array acquisition

Pfizer Inc PFE announced that an interim futility analysis of the global Phase 3 trial, REALM-DCM of PF-07265803, indicated the trial is unlikely to meet its primary endpoint upon completion.
Based on these results, the Phase 3 trial and further development of PF-07265803 will be discontinued. This decision is not based on safety concerns.
Patients enrolled in the Phase 3 trial will stop study medication and complete any necessary follow-up evaluations. Detailed data from the REALM-DCM study will be presented at future medical meetings to help inform ongoing research.
The asset was added when Pfizer acquired Array BioPharma for $11.4 billion in 2019, mainly focused on oncology but included a few non-cancer assets, including a Phase 3 drug being tested in a rare cardiovascular disease.
Pfizer was testing PF-07265803, formerly ARRY-797, in patients with symptomatic dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA).
LMNA-related DCM involves left ventricular enlargement and/or reduced systolic function. Arrhythmias and conduction system disease also sometimes accompany the rare inherited condition.
Price Action: PFE shares are down 0.22% at $49.75 during the market session on the last check Thursday.

Momentum28.59

Growth96.90

Quality64.13

Value30.40

Short

Medium

Long